KFDA to evaluate risk of cardiovascular events with sibutramine

Published: 2010-04-16 17:06:00

Updated: 2010-04-16 17:06:00

The Korea Food and Drug Administration says it is reviewing final data from a recent study (SCOUT) suggesting that patients using sibutramine have a higher number of cardiovascular events than patients receiving placebo.

The study findings highlight the importance of avoiding the use of sibutr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK